Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Acute Effect of Resistance Exercise in Individuals With Hypertrophic Cardiomyopathy: A Pilot Study.

The American journal of cardiology·2026
Same author

Prevalence and Predictors of Cardiac Troponin Elevations Following Exercise: a Systematic Review, Meta-analysis, and Meta-regression.

European journal of preventive cardiology·2026
Same author

Masters athletes with abnormal cardiovascular findings: a clinical consensus statement of the European Association of Preventive Cardiology of the ESC and the American College of Cardiology.

European heart journal·2026
Same author

Masters Athletes With Abnormal Cardiovascular Findings: A Clinical Consensus Statement of the European Association of Preventive Cardiology of the ESC and the American College of Cardiology.

Journal of the American College of Cardiology·2026
Same author

Syncope During Cycling.

JACC. Case reports·2026
Same author

Spatial localization and pharmacodynamic assessment of intracrine androgen metabolism in CRPC xenograft tumor tissues upon active vitamin D treatment.

Analytical and bioanalytical chemistry·2026

Related Experiment Videos

Ezetimibe-related myopathy: A systematic review.

Hanna Slim1, Paul D Thompson

  • 1Hospital of Saint Raphael, New Haven, CT, USA.

Journal of Clinical Lipidology
|February 5, 2011
PubMed
Summary

Ezetimibe is generally safe and well-tolerated, with no increased risk of myopathy when used alone or with statins. Rare cases of muscle disorders may be linked to ezetimibe, but evidence is limited.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Clinical Therapeutics

Background:

  • Ezetimibe is a cholesterol absorption inhibitor used for managing hyperlipidemia.
  • While generally safe, there are concerns regarding potential myopathy associated with ezetimibe use.
  • Understanding its safety profile, especially in combination with statins, is crucial for clinical practice.

Purpose of the Study:

  • To evaluate the safety of ezetimibe, focusing on the incidence of myopathy.
  • To determine if ezetimibe monotherapy or combination therapy with statins increases the risk of musculoskeletal disorders.
  • To review existing literature on ezetimibe-associated myopathy.

Main Methods:

  • A comprehensive PubMed search was conducted for English-language articles up to April 2008.

Related Experiment Videos

  • The search focused on studies examining ezetimibe safety as monotherapy or in combination with lipid-lowering agents.
  • Case reports and clinical trial data on musculoskeletal disorders were analyzed.

    • Main Results:

    • Clinical trials showed identical incidences of musculoskeletal disorders for ezetimibe alone versus placebo.
    • Combination therapy with statins yielded similar rates of muscle disorders compared to statin monotherapy.
    • Only six case reports suggested a possible link between ezetimibe and myopathy.

    Conclusions:

    • Ezetimibe does not appear to cause or worsen statin-induced myopathy in most patients.
    • The risk of myopathy associated with ezetimibe is very low, potentially occurring only in rare instances.
    • Ezetimibe demonstrates a favorable safety profile regarding muscle-related adverse events.